Display options
Cite
Ciampricotti M, Karakousi T, Richards AL, et al. . Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-0441.
Ciampricotti, M., Karakousi, T., Richards, A. L., Quintanal-Villalonga, �. �., Karatza, A., Caeser, R., Costa, E. A., Allaj, V., Manoj, P., Spainhower, K. B., Kombak, F. E., Sanchez-Rivera, F. J., Jaspers, J. E., Zavitsanou, A. M., Maddalo, D., Ventura, A., Rideout, W. M., Akama-Garren, E. H., Jacks, T., Donoghue, M. T. A., Sen, T., Oliver, T. G., Poirier, J. T., Papagiannakopoulos, T., & Rudin, C. M. (2021). . Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-0441
Ciampricotti, Metamia, et al. "." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-0441
Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga À, Karatza A, Caeser R, Costa EA, Allaj V, Manoj P, Spainhower KB, Kombak FE, Sanchez-Rivera FJ, Jaspers JE, Zavitsanou AM, Maddalo D, Ventura A, Rideout WM, Akama-Garren EH, Jacks T, Donoghue MTA, Sen T, Oliver TG, Poirier JT, Papagiannakopoulos T, Rudin CM. . Cancer Discov. 2021 Aug 03; doi: 10.1158/2159-8290.CD-21-0441. Epub 2021 Aug 03. PMID: 34344693.
Copy Download .nbib Format: NLM
Share it on

Cancer Discov. 2021 Aug 03; doi: 10.1158/2159-8290.CD-21-0441. Epub 2021 Aug 03.

[No title available]

Cancer discovery

Metamia Ciampricotti, Triantafyllia Karakousi, Allison L Richards, Àlvaro Quintanal-Villalonga, Angeliki Karatza, Rebecca Caeser, Emily A Costa, Viola Allaj, Parvathy Manoj, Kyle B Spainhower, Faruk E Kombak, Francisco J Sanchez-Rivera, Janneke E Jaspers, Anastasia-Maria Zavitsanou, Danilo Maddalo, Andrea Ventura, William M Rideout, Elliot H Akama-Garren, Tyler Jacks, Mark T A Donoghue, Triparna Sen, Trudy G Oliver, John T Poirier, Thales Papagiannakopoulos, Charles M Rudin

Affiliations

  1. Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  2. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  3. Department of Pathology, New York University School of Medicine, New York, New York.
  4. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  5. Perlmutter Cancer Center, New York University Langone Health, New York, New York.
  6. Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York.
  7. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  8. Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, New York.
  9. Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  10. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  11. David H. Koch Institute for Integrative Cancer Research, Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  12. Department of Pathology, New York University School of Medicine, New York, New York. [email protected] [email protected].
  13. Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. [email protected] [email protected].

PMID: 34344693 DOI: 10.1158/2159-8290.CD-21-0441

Abstract

Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in SCLC, most notably an in-frame gene fusion between

©2021 American Association for Cancer Research.

Publication Types

Grant support